Variable | Cohort | Alive at 2 years | Univariable regression analysis (n=22 967) | ||||
---|---|---|---|---|---|---|---|
n | n | % | OR | 95% CI | p Value | ||
Deprivation (IMD) quintile | 22 967 | 3513 | 15.3 | 0.004 | |||
1 (least deprived) | 2698 | 474 | 17.6 | 1.00 | |||
2 | 3303 | 520 | 15.7 | 0.88 | 0.76 | 1.00 | 0.059 |
3 | 3827 | 586 | 15.3 | 0.85 | 0.74 | 0.97 | 0.015 |
4 | 5387 | 815 | 15.1 | 0.84 | 0.74 | 0.95 | 0.005 |
5 (most deprived) | 7752 | 1118 | 14.4 | 0.79 | 0.70 | 0.89 | <0.001 |
Age group (years) | 22 967 | 3513 | 15.3 | <0.001 | |||
<60 | 3041 | 651 | 21.4 | 1.00 | |||
60–69 | 6016 | 1199 | 19.9 | 0.91 | 0.82 | 1.02 | 0.100 |
70–79 | 8219 | 1210 | 14.7 | 0.63 | 0.57 | 0.70 | <0.001 |
80+ | 5691 | 453 | 8.0 | 0.32 | 0.28 | 0.36 | <0.001 |
Sex | 22 967 | 3513 | 15.3 | <0.001 | |||
Female | 10 510 | 1770 | 16.8 | 1.00 | |||
Male | 12 457 | 1743 | 14.0 | 0.80 | 0.75 | 0.86 | <0.001 |
Histology | 22 967 | 3513 | 15.3 | <0.001 | |||
NSCLC | 12 152 | 2463 | 20.3 | 1.00 | |||
SCLC | 2829 | 236 | 8.3 | 0.36 | 0.31 | 0.41 | <0.001 |
Other | 7986 | 814 | 10.2 | 0.45 | 0.41 | 0.49 | <0.001 |
Year of diagnosis | 22 967 | 3513 | 15.3 | <0.001 | |||
2006 | 5533 | 783 | 14.2 | 1.00 | |||
2007 | 5712 | 844 | 14.8 | 1.05 | 0.95 | 1.17 | 0.347 |
2008 | 5851 | 861 | 14.7 | 1.05 | 0.94 | 1.16 | 0.392 |
2009 | 5871 | 1025 | 17.5 | 1.28 | 1.16 | 1.42 | <0.001 |
Comorbidity (CCI) score | 22 967 | 3513 | 15.3 | 0.001 | |||
0 | 3597 | 601 | 16.7 | 1.00 | |||
1–2 | 3125 | 453 | 14.5 | 0.85 | 0.74 | 0.97 | 0.013 |
3+ | 766 | 89 | 11.6 | 0.66 | 0.52 | 0.83 | <0.001 |
Missing | 10 133 | 1509 | 14.9 | 0.87 | 0.79 | 0.97 | 0.009 |
Unavailable | 5346 | 861 | 16.1 | 0.96 | 0.85 | 1.07 | 0.450 |
Timely GP referral | 22 967 | 3513 | 15.3 | <0.001 | |||
FHA>14 days from referral | 3669 | 803 | 21.9 | 1.00 | |||
FHA≤14 days from referral | 8284 | 1456 | 17.6 | 0.76 | 0.69 | 0.84 | <0.001 |
No GP referral date | 11 014 | 1254 | 11.4 | 0.46 | 0.42 | 0.51 | <0.001 |
Stage | 22 967 | 3513 | 15.3 | <0.001 | |||
I | 864 | 504 | 58.3 | 1.00 | |||
II | 332 | 128 | 38.6 | 0.45 | 0.35 | 0.58 | <0.001 |
III | 1587 | 276 | 17.4 | 0.15 | 0.12 | 0.18 | <0.001 |
IV | 2450 | 139 | 5.7 | 0.04 | 0.03 | 0.05 | <0.001 |
Missing | 17 734 | 2,466 | 13.9 | 0.12 | 0.10 | 0.13 | <0.001 |
Performance status | 22 967 | 3,513 | 15.3 | <0.001 | |||
0 | 1,298 | 481 | 37.1 | 1.00 | |||
1–2 | 3414 | 635 | 18.6 | 0.39 | 0.34 | 0.45 | <0.001 |
3–4 | 1415 | 65 | 4.6 | 0.08 | 0.06 | 0.11 | <0.001 |
Missing | 16 840 | 2332 | 13.9 | 0.27 | 0.24 | 0.31 | <0.001 |
Type of treatment | 22 967 | 3513 | 15.3 | <0.001 | |||
no treatment | 10 675 | 459 | 4.3 | 1.00 | |||
Surgery | 1427 | 1041 | 73.0 | 60.02 | 51.68 | 69.71 | <0.001 |
Surgery + chemotherapy and/or radiotherapy | 809 | 521 | 64.4 | 40.26 | 33.91 | 47.80 | <0.001 |
Chemotherapy | 2759 | 267 | 9.7 | 2.38 | 2.04 | 2.79 | <0.001 |
Chemotherapy + radiotherapy | 3236 | 701 | 21.7 | 6.15 | 5.43 | 6.98 | <0.001 |
Radiotherapy | 4061 | 524 | 12.9 | 3.30 | 2.89 | 3.76 | <0.001 |
Timely 1st treatment | 22 967 | 3513 | 15.3 | <0.001 | |||
>31 days from diagnosis | 7443 | 2346 | 31.5 | 1.00 | |||
≤31 days from diagnosis | 4849 | 708 | 14.6 | 0.37 | 0.34 | 0.41 | <0.001 |
No treatment | 10 675 | 459 | 4.3 | 0.10 | 0.09 | 0.11 | <0.001 |
CCI score, Charlson Comorbidity Score; FHA, first hospital appointment; IMD, Index of Multiple Deprivation; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.